Aging
Navigate
Submit an Article
Research Paper|Volume 15, Issue 15|pp. 7476–7495
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Back to articleFigure 1(1 of 6)
100%
Figure 1
Figure 1.The detailed work process of this study. SETBP1 mutations were determined as a potential biomarker for melanoma and NSCLC clinical ICI treatments.